• Home
  • NEW DAY MEDICINE
  • 8 (70) 2024
  • 27 -8 (70) 2024 - Assesorova Yu.Yu., Samarina K.S. - THE HEMOSTASIS SYSTEM AND CHARACTERISTICS OF ITS DISORDERS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

27 -8 (70) 2024 - Assesorova Yu.Yu., Samarina K.S. - THE HEMOSTASIS SYSTEM AND CHARACTERISTICS OF ITS DISORDERS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

THE HEMOSTASIS SYSTEM AND CHARACTERISTICS OF ITS DISORDERS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

Assesorova Yu.Yu. - Republican Specialized Scientific and Practical Medical Hematology Center

Samarina K.S. - Republican Specialized Scientific and Practical Medical Hematology Center

Resume

The review article introduces modern ideas about the mechanisms of activation of thrombus formation and antithrombotic processes occurring during the operation of the hemostasis system, the prevalence, pathogenesis, consequences and aspects of the treatment of thrombophilic conditions in patients with Ph-negative and Ph-positive myeloproliferative neoplasms (MPNs). The data presented in the review are the result of analysis and generalization of the results of global research. Knowledge of the basics of the hemostasis system and understanding of the functional purpose of the factors that activate its coagulation and anticoagulation mechanisms will be of clinical importance, since one of the goals of treatment of MPNs is to reduce the risk of thrombosis. Modern concepts of therapy for Ph-positive and Ph-negative MPNs must properly take into account risk factors associated with disorders in the hemostasis system.

Keywords: myeloproliferative neoplasms, chronic myeloid leukemia, hemostasis, thrombophilia.

First page

149

Last page

157

For citation:Assesorova Yu.Yu., Samarina K.S. - THE HEMOSTASIS SYSTEM AND CHARACTERISTICS OF ITS DISORDERS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS//New Day in Medicine 8(70)2024 149-157 https://newdayworldmedicine.com/en/new_day_medicine/8-70-2024

List of References

  1. Appelmann I, Kreher S, Parmentier S, et al. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the hemostasis working Party of the German Society of hematology and medical oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH) // Ann Hematol. 2016;95(5):707-718. doi: 10.1007/s00277-016-2621-2.
  2. Arber D.A., Orazi A., Hasserjian R.P., et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.
  3. Barranco-Lampón G, Martínez-Castro R, Arana-Luna L, et al. Thrombotic events. Gac Med Mex. 2022;158(Supl 1):45-54. English. doi: 10.24875/GMM.M22000806.
  4. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;10;34(20):2333-40. doi: 10.1200/JCO.2015.64.8899.
  5. Cortes J.E., Jimenez C.A., Mauro M.J., Geyer A., Pinilla-Ibarz J., Smith B. D. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. //Clin. Lymphoma Myeloma Leuk. 2017;17(2):78-82. 10.1016/j.clml.2016.09.012
  6. Dambrauskienė R, Gerbutavičius R, Rudžianskienė M, et al. Antiphospholipid antibodies and the risk of thrombosis in myeloproliferative neoplasms. //Open Life Sci. 2023 Feb 7;18(1):20220545. doi: 10.1515/biol-2022-0545.
  7. Fukatsu M, Ikezoe T. Cancer-associated thrombosis in hematologic malignancies. Int J Hematol. 2024 May;119(5):516-525. doi: 10.1007/s12185-023-03690-z. Epub 2024 Jan 25. PMID: 38270784.
  8. Haguet H, Bouvy C, Delvigne AS, Modaffari E, Wannez A, Sonveaux P, Dogné JM, Douxfils J. The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study. //Front Pharmacol. 2020 Jul 3;11:1007. doi: 10.3389/fphar.2020.01007. PMID: 32719607; PMCID: PMC7350860.
  9. Haguet H., Douxfils J., Chatelain C., Graux C., Mullier F., Dogné J.-M. (2018). BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis? //TH Open 2018;2(1):68-88. 10.1055/s-0038-1624566
  10. Hochhaus A., Saglio G., Hughes T. P., et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. //Leukemia. 2016;30(5):1044-1054. 10.1038/leu.2016.5
  11. Kaifie A, Kirschner M, Wolf D, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. //J Hematol Oncol. 2016 Mar 5;9:18. doi: 10.1186/s13045-016-0242-9.
  12. Khoury J.D., Solary E., Abla O., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1.
  13. Knöfler R, Lange BS, Paul F, Tiebel O, Suttorp M. Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukaemia in children. //Br J Haematol. 2020 Mar;188(5):701-706. doi: 10.1111/bjh.16241.
  14. Liu, Z., Fan, H., Li, Y. , Liu, C. Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors. //Oncology Targets Therapy, 2017;10:3515-3520.
  15. Minson A. G., Cummins K., Fox L., Costello B., Yeung D., Cleary R., et al. (2019). The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia. //Blood Adv. 2019;3(7)1084-1091. 10.1182/bloodadvances.2018028035
  16. Molica M, Massaro F, Breccia M. Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update. //Expert Rev Mol Diagn. 2017 Nov;17(11):1001-1008. doi: 10.1080/14737159.2017.1383156.
  17. Pfirrmann M, Lauseker M, Hoffmann VS, Hasford J. Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death. Ann Hematol. 2015 Apr;94(2):209-18. doi: 10.1007/s00277-015-2316-0.
  18. Rungjirajittranon T, Owattanapanich W, Ungprasert P, et al. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. //BMC Cancer. 2019 Feb 28;19(1):184. doi: 10.1186/s12885-019-5387-9.
  19. Saglio G., le Coutre P., Cortes J., Mayer J., Rowlings P., Mahon F. X., et al. (2017). Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. //Ann. Hematol 2017;96:1303-1313. 10.1007/s00277-017-3012-z
  20. Song IC, Yeon SH, Lee MW, et al. Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm. //Korean J Intern Med. 2021 Sep;36(5):1190-1203. doi: 10.3904/kjim.2020.634.

    file

    download